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Available online 20 May 2011Research into muscle atrophy and hypertrophy is hampered by limitations of the available
experimental models. Interpretation of in vivo experiments is confounded by the complexity of the
environment while in vitro models are subject to the marked disparities between cultured
myotubes and the mature myofibres of living tissues. Here we develop a method (PhAct) based on
ex vivo maintenance of the isolated myofibre as a model of disuse atrophy, using standard
microscopy equipment and widely available analysis software, to measure f-actin content per
myofibre and per nucleus over two weeks of ex vivo maintenance. We characterize the 35% per
week atrophy of the isolatedmyofibre in terms of early changes in gene expression and investigate
the effects on loss of muscle mass of modulatory agents, including Myostatin and Follistatin. By
tracing the incorporation of a nucleotide analogue we show that the observed atrophy is not
associated with loss or replacement of myonuclei. Such a completely controlled investigation can
be conducted with the myofibres of a single muscle. With this novel method we can distinguish
those features and mechanisms of atrophy and hypertrophy that are intrinsic to the muscle fibre
from those that include activities of other tissues and systemic agents.
© 2011 Elsevier Inc. All rights reserved.Keywords:
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Methods for the isolation and ex vivo maintenance of intact single
myofibres have been known for some years [1,2]. The isolated
muscle fibre has proved useful in the study of satellite cell
behaviour ex vivo[3] and in vivo[4] but the cell biology of the
myofibre itself has largely been neglected. Atrophy of themyofibre
is an important component of numerous human conditions,
including aging, bed-rest, sepsis, and many neuromuscularg (W.J. Duddy), tcohen@cn
ine; EDL, Extensor Digitor
rotein-1; Eif4ebp1, PHAS-1
κB, nuclear factor kappa-lig
r Inc. All rights reserved.disorders, and loss of muscle mass is a risk factor for post-
operative morbidity (reviewed [5]).
Changes in muscle mass in the living animal have been
assessed by a range of methods from gross measurements of
whole muscle protein content [6–9] or inferences from muscle
cross-sections [10–12], to low-throughput intensive analyses of
confocalized z-stacks [13]. Such investigations are labor- and
animal-intensive, largely restricting investigation to very specific
mechanisms or modulatory agents. Moreover, because of themcresearch.org (T. Cohen), sduguez@cnmcresearch.org (S. Duguez),
um Longus; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel
, Eukaryotic translation initiation factor 4E-binding protein 1; eIF-4E,
ht-chain-enhancer of activated B cells; TNFα, Tumor necrosis factor-
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animal, they are necessarily empirical in nature and cannot be
used to rigorously investigate specific mechanisms. A second
general approach has been to extrapolate from the behaviour of in
vitro cultures of myotubes [14–16]. The less intensive of these
methods are generally inadequate to determine change in the
volume of cytoplasm served by each myonucleus, the size of the
myonuclear domain (MND). Loss of MND size is a near-universal
observation following in vivo atrophy [13,17–27], and is usually
determined by combination of the methods above with counts of
myonuclei per millimeter of myofibre, itself a method not immune
to error, since it does not take account of myofibre length.
Various compounds are shown or suggested to influence
myofibre size, some of which potentially affect the rate of atrophy.
The Activin type II receptor agonist, Myostatin, a negative
regulator of muscle mass [28], and its inhibitor Follistatin [29]
are of major current interest, on the expectation that increased
muscle mass resulting from the inhibition of myostatin activity
might protect against atrophic stimuli. Putative positive regulators
of muscle mass include the insulin-like growth factor, IGF-1
(reviewed [30]), and the metabolite, Leucine [31]. The study of
musclemass regulation is limited by currentmodels because of the
complexity of the in vivo muscle environment and the question-
able relationship of in vitro tissue culture to the in vivo system.
Here the ex vivo maintenance of the isolated myofibre is
evaluated as a potential tool for the study of atrophy induced by
denervation and lack of work. We propose that it represents a
model intermediate between in vivo and in vitro approaches in that
the atrophic environment may be carefully controlled whilst
retainingmuch of the phenotypic character of living muscle tissue.
A further advantage is the reduction of animal requirements, since
a fully controlled experiment may be conducted with the
myofibres from a single muscle. We present a novel method for
the sensitive measurement of contractile actin content per
myofibre that when combined with counts of nuclei per myofibre
gives the f-actin content per nucleus, an indicator of the myo-
nuclear domain size. We call this method PhAct, a contraction of
Phalloidin-based Actin quantification. Atrophy-associated myo-
nuclear loss is assayed in myofibres isolated from the extensor
digitorum longus (EDL) muscles of transgenic mice expressing a
myonuclear marker. Incorporation of the nucleotide analogue, 5-
ethynyl-2′-deoxyuridine (EdU), is used to investigate myonuclear
accretion or replacement during atrophy. Early changes in gene
expression are characterized, and the effects on the rate of atrophy
induced by several putative regulators of muscle mass (Myostatin,
Follistatin, and Leucine) are measured.Materials and methods
Animal use
Two mouse lines were used in this study: wild-type C57BL/10SnJ
(JAX Mice), and the transgenic strain 3F-nLacZ-e (M. Bucking-
ham). The 3F-nLacZ-emouse is on a C57BL/6 X SJL background and
expresses LacZ protein driven from a myonuclear specific
promoter, myosin light chain type 3F [32]. Three-month old
male mice were used as by this age the EDL muscle has attained
full adult size and provides a stable basis for comparison of rates of
atrophy in response to a given treatment. Sufficient myofibreswere isolated from a single animal by pooling myofibres from the
two EDL muscles for each experiment, except for analysis of gene
expression, for which three animals were used per time-point and
a single sample of 180 myofibres was collected from each animal.
All animal procedures were performed according to Children's
National Medical Center Institutional Animal Care and Use
Committee, and National Institutes of Health guidelines.
Isolation of myofibres
Reagents were from Invitrogen unless otherwise stated. Single
myofibres were isolated as described previously [3]. Briefly:
extensor digitorum longus (EDL) muscles were carefully dissected
immediately after euthanasing the mouse and incubated in 0.2%
Collagenase Type 1 (Sigma) in DMEM for 1 to 2 h, depending on
muscle size, to digest the connective tissue. Single myofibres were
liberated by trituration with fire-smoothedwide-mouthed Pasteur
pipettes in dishes containing DMEM and pre-coated with horse
serum (to prevent adherence); liberated myofibres were washed
by transfer through four such dishes.
Ex vivo maintenance and treatment of myofibres
Isolated myofibres were maintained in free-floating suspension in
deep-sided dishes (Sterilin) coated with horse serum and contain-
ing DMEM (with 4500 mg/L D-glucose, L-glutamine, and 110 mg/L
sodium pyruvate) with the following additional components: 10%
v/v horse serum, 2% v/v (4 mM) L-glutamine (Sigma), and 1% v/v
Penicillin/Streptomycin (Sigma). Twenty-five myofibres were
placed in each dish. Half of the medium was removed and
replaced with fresh medium every 3 days in culture. Dishes were
swirled briefly in a gentle circular motion once per day to guard
against tangling of myofibres.
Test compounds were added directly to the culture medium at
various concentrations daily or every three days, as listed in the
results section: Recombinant Mouse Follistatin (R & D systems),
Recombinant Mouse GDF-8/Myostatin (R & D systems), and
Leucine (Sigma).
Fixation and staining of myofibres for assay of f-actin content
and counting of nuclei
Batches of myofibres were harvested at each time-point by
transferring them to a 2 ml Eppendorf vial containing 1.5 ml
3.65% Formaldehyde, in which they were fixed at 37 °C for 15 min.
The vial was centrifuged at 700 g for 10 min, causing themyofibres
to form a loose pellet, delicately attached to the bottom of the vial.
The formaldehyde solution was removed carefully with a Pasteur
pipette so as not to disturb the pellet then 1 ml of 30% sucrose was
added. The myofibres were resuspended using a brief (3 s) vortex
then stored at −80 °C until staining.
The Eppendorf vial containing fixed myofibres in 30% sucrose
was allowed to thaw and the contents were deposited into a Petri
dish. To ensure that all of the myofibres were removed from the
Eppendorf it was rinsed once with a solution of TBS-tween (Tween
0.1% in TBS) whichwas deposited into the same Petri dish. Because
the density of the sucrose prevented pelleting of the fibers we used
a stereo microscope and watchmakers forceps to transfer
myofibres carefully into a 2 ml Eppendorf vial containing permea-
bilization and blocking buffer (Triton 0.5%, Tween 0.1%, BSA 2%,
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at 4 °C the vial was centrifuged for 10 min at 15,000 g. The buffer
was removed and 1 ml of rinse solution (TBS-tween) was added.
The myofibres were resuspended with a brief (3 sec) vortex, then
centrifuged for a further 10 min at 15,000 g. This rinse step was
repeated 3 times. Myofibres were then resuspended in Alexa Fluor
594 conjugated Phalloidin for 20 min at room temperature at a
dilution of 1:40 unless otherwise stated. After 3 more rinses the
fibres were left in the rinse solution overnight at 4 °C to maximize
removal of unbound Phalloidin. After centrifugation for 10minutes
at 15,000 g, myofibres were resuspended in a 0.75 μg/ml solution
of DAPI and immediately centrifuged a further 10 min at 15,000 g,
then rinsed once more. The contents of the vial were deposited
into a Petri dish and the vial was rinsed once to ensure removal of
all myofibres from the Eppendorf. A stereo microscope and forceps
were used to transfer the myofibres gently onto a microscope slide
on which they were mounted.
Imaging and software analysis
Stained myofibres were imaged on standard epifluorescence micros-
copy equipment: a Nikon Eclipse E500microscopewith Spot Camera.
A Nikon PlanApo 10× objective was used to image adjacent
overlapping segments of each myofibre. Between 2 and 6 images
were required, depending on the length of the myofibre. Initially,
exposure time was set to fall within a range of signal intensity that
was validated to elicit a linear response inmeasured signal. Exposure
time was then kept constant across all samples compared.
Images of the myofibre were stitched together using the‘Inter-
active Layout’ mode of the Photomerge feature of Adobe Photo-
shop. Interactive layout is the default mode for Adobe Photoshop
version CS2 and is available in current versions of Adobe Photo-
shop Elements, but is absent from some later versions of Adobe
Photoshop such as CS4, for which a ‘PhotomergeUI’ plug-in, from
Adobe, may be required. The ‘Snap to image’ feature of the
Interactive Layout mode was found to respond best to color-
inverted images (i.e. presenting the myofibre on a white
background as opposed to the black background of the original
image).
The total signal intensity of stitched images was measured
using ImageJ (http://rsbweb.nih.gov/ij/). Each image was unin-
verted following stitching in Photoshop, and then converted into a
32-bit image. Lower threshold for pixel quantificationwas set to ‘1’
to eliminate background pixels, with non-thresholded pixels set to
the NaN (Not a Number) value, and then the integrated density
(total signal) of the image was quantified. An imageJ Macro named
‘PhAct’was created to facilitate batch operations of the above steps
on multiple images (http://rsbweb.nih.gov/ij/macros/).
For confocal microscopy, z-stacks were acquired using a Zeiss
LSM 510 Meta NLO system with an Axiovert 200 M microscope.
Depths ranged from 35.3 to 61.8 μm, depending on myofibre
thickness. Slices 2.2 μm thick composed of 512 by 512 pixels were
collected with 20× objective. Between 2 and 6 non-adjacent z-
stacks were collected per myofibre, depending onmyofibre length.
DAPI-stained nuclei were counted for each z-stack by eye from 3D
representation using Axiovision software (Zeiss) and added
together for each myofibre. ImageJ was used to calculate the
integrated density of signal from Fluorophore-conjugated Phalloi-
din for each slice, which were added together to give total signal
per z-stack. Signals per z-stack were added for each myofibre anddivided by the number of nuclei to give signal per nucleus, which
was normalized to the average signal per nucleus of the myofibres
from 28 week old mice.
Confirmation of equipment sensitivity and consistency
A 10 μl drop of fluorophore conjugated Phalloidin of fixed
concentration (1:4 in H2O) was used as a standard signal. Imaging
of this at various exposure times confirmed that measured signal
increased in linear proportion to actual signal. Averages of four
images were taken per exposure time . ImageJ was used to
calculate the mean pixel intensity for each field. A minor
adjustment is made to measurements of signal intensity according
to the y-intercept of the plot of mean pixel intensity against
exposure time. Imaging of this standard signal can be used to
normalize data across different experimental series.
Measurement of protein content of isolated myofibres
To investigate the extent to which f-actin protein content is
reflective of total protein content, total protein was measured on
batches of twenty myofibres by quantifying silver stain intensities
of whole protein extracts separated out by SDS-PAGE. We
compared batches at two time-points (Day 0 and Day 9). Silver
stain was chosen due to its greater sensitivity over others such as
Coomassie Blue. Briefly, isolated myofibres were placed in protein
extraction buffer (NaCl 300 mM, NaH2PO4 100 mM, Na2HPO4
50 mM, Na4P2O7 10 mM, MgCl2×6H2O 1 mM, EDTA 10 mM, 2-β-
mercaptoethanol 0.7% (Sigma), with protease inhibitor cocktail
according to manufacturer’s instructions (Roche)) and stored at
−20 °C. Samples were homogenized by freezing and thawing
three times, treated with DNase, and passed through a fine-gauge
syringe. For loading, two parts sample were mixed with two parts
glycerol and one part loading buffer (NuPage 4×+50 mM DTT,
Sigma). Polyacrylamide gel (8%) was run for 55 min at 150 V in
MOPS buffer. Gels were silver stained according to manufacturer’s
instructions (Sigma) and imaged. Analysis was carried out using
ImageJ. All bands were quantified except the one corresponding to
serum albumin (60 kDa), a contaminant from the myofibre
isolation procedure.
Immunostaining of myonuclei and adherent cell nuclei, and
labeling of proliferating nuclei
To immunostain myonuclei and adherent cell nuclei myofibres
were incubated with primary antibodies for 2 h at room
temperature following the permeabilization and blocking step
then rinsed 3 times and incubated with secondary antibodies for
1 h at room temperature followed by 2 rinses and one overnight
rinse step to minimize non-specific background staining of
myofibres. Myonuclei of myofibres isolated from the 3F-nLacZ-e
mousewere immunostained using Rabbit IgG Anti β-Galactosidase
primary antibody (1:300 dilution) and Alexa Fluor 594 anti-rabbit
secondary antibody (1:400 dilution). Myonuclei were immunos-
tained using a mixture of two mouse IgG1 primary antibodies,
anti-Pax7 (Developmental Studies Hybridoma Bank; undiluted)
and anti-MyoD (Vector labs; 1:25 dilution), and the Alexa Fluor-
488 anti-mouse IgG1 secondary (1:400 dilution). This co-stain
marks both quiescent (Pax7 expressing) and activated (MyoD
expressing) myoblasts.
Fig. 1 – Assay of f-actin content using the PhAct method.
(A) Micrograph collage of a representative isolated myofibre.
Signal from f-actin-bound Alexa Fluor 594 conjugated
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were maintained in culture in the presence of the nucleotide
analogue, 5-ethynyl-2′-deoxyuridine (EdU). DNA containing EdU
was labeled using the Click-iT EdU Alexa Fluor 594 Imaging Kit,
and adapting from the manufacturer's instructions. The method
was similar to that described for the staining of f-actin using
Phalloidin, except that myofibres were permeabilized with 0.5%
Triton in PBS for 20 min at room temperature, then incubated with
the EdU Click-iT reaction cocktail for 30 min at room temperature
prior to the overnight permeabilization and blocking step.
Microarray mRNA expression profiling and quantitative
real-time PCR
RNAwas extracted from triplicate batches of 180 isolatedmyofibres
at days 0, 1, and 2, of ex vivo culture. Myofibres were placed into
culture medium contained in BSA-coated round-bottomed glass
vials and allowed to settle for 2 min at the bottom of the vial.
Mediumwas then replaced by 1 ml of Trizol, in which themyofibres
were triturated by 50 passes through a 1 ml pipette tip. Each batch
was then stored at −80 °C prior to purification on RNeasy spin
columns (Qiagen). Approximately 120 ng of total RNAwas obtained
from each batch of 180 myofibres. Total RNA was amplified (two-
cycle) and hybridized to Affymetrix GeneChipMouse Expression Set
430 2.0 according to the manufacturer's instructions (Affymetrix
USA). Gene expression data analysis was performed using the probe
set algorithms MAS5.0 and dCHIP and data visualization and
statistical analyses using GeneSpring Software (Stratagene). Hierar-
chical Clustering Analysis showed clustering of batches in accor-
dance with time-points (data not shown). Candidate probe sets
showing changes between time-points were selected based upon
their concordance in MAS5.0 and dChip algorithms with a Welch
ANOVA t-test of p<0.05 compared with day 0.
Fifty-six mRNA transcripts of interest were selected and
confirmed by RT-PCR. Samples independent from gene profiling
experimentswereused for validation studies. Total RNAwas isolated
as above and 22 ng of total RNA was used with 1st Strand cDNA
Synthesis Kit (Roche) to generate cDNA. The cDNA was added to
SYBRGreen PCRMasterMix (Applied Biosystems) and real time PCR
was performed using the 7900 HT Fast Real Time PCR system
(Applied Biosystems) in the relative quantificationΔΔct mode. Data
was analyzed using manufacturer supplied SDS2.3 software.
Statistical analyses
Student's T-test was used throughout unless otherwise stated.
Figure captions indicate p-values and 95% confidence intervals.
Linear regressions are shown where f-actin signal is plotted
against number of nuclei or average signal per nucleus is plotted
against concentration of phalloidin.Phalloidin is shown in red. For illustrative purposes this is
merged with DAPI stained nuclei shown in blue and with
transmitted light images. Overlapping fields were stitched
together to facilitate quantification of whole myofibre f-actin
content. Scale bar=500 μm. (B) The linear relationship of
f-actin content to number of nuclei per myofibre. Each datum
represents a single myofibre from the EDL muscle of a
3 month-old wild-type mouse. Whole myofibre f-actin content
is measured as a relative quantity so units are arbitrary, as
described in the Materials and Methods.Results
Anovelmethod (PhAct) usingphalloidin-staining to quantify f-
actin content per myofibre
Wewished to determinewhether atrophic changes aremanifested
in isolated single myofibres maintained in tissue culture ex vivo,
and whether those changes are associated with loss or gain ofmyonuclei. We hypothesized that f-actin content would decline
with ex vivo culture time, whilemyonuclear number would remain
unchanged, together reflecting a reduction in size of the myo-
nuclear domain. To test these hypotheses we developed a
microscopy-based method whereby f-actin content is quantified
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isolated from the EDL muscles of 3 month old male Bl10 mice, at
which age, growth has ceased.
We find a directly proportional relationship between the total
f-actin signal per myofibre and the number of nuclei per myofibre
(Fig. 1B), such that a doubling of nuclear number is associatedwith
an approximate doubling of actin signal. This relationship is
consistent with previous reports in suggesting that, within the
adult mouse EDL muscle, average myonuclear domain size does
not vary greatly between myofibres [33].
We chose a concentration (1:40 dilution, or 0.025 v/v) of
fluorophore-conjugated Phalloidin that did not saturate measured
signal intensities (Fig. 2A). A validation of themethod requires thatFig. 2 – Validation of PhAct method. (A) Average ratios of f-actin sig
Fluor 594 conjugated Phalloidin is prepared at 300 units / ml accord
2% BSA. The relationship is linear for a range of concentrations that
For each concentration the signal per nucleus ratios of 4–5 myofibr
actual signal. Average pixel intensity was measured of a solution of
times. (C) Confocalized signal per nucleus matches well to the non
muscles of 28 week old and 2 week old male Bl10 mice, respectively
of the 28 week old myofibres for each data set. (D) Alexa Fluor 594
myofibre volume. The upper panel shows a central slice from the z-s
line section. The lower panel shows signal intensity values along th
myofibre.the microscopy equipment is equally sensitive at all values of
fluorescence intensity, within the range of values exhibited by the
stainedmyofibres. Intensity values frommyofibres at the exposure
time (50 ms) and Phalloidin concentration (1:40) used were in the
range 6–10 units per pixel. We show that the measured signal was
linear across a range of exposure times of a solution of
fluorophore-conjugated Phalloidin within the range 3–14 units
per pixel (Fig. 2B). No measurable bleaching occurred between
exposures (data not shown).
To further validate the epifluorescence microscopy method we
present here we compared values with those obtained from
confocal z-stacks. With the standard epifluorescent microscope
loss of signal may arise due to portions of the sample lying outsidenal per nucleus at different concentrations of Phalloidin. Alexa
ing to themanufacturer's instructions, then diluted in PBS with
includes that used for the experiments described (5 units / ml).
es are averaged. (B) Measured signal is directly proportional to
Alexa Fluor 594 conjugated Phalloidin over a range of exposure
-confocalized signal. Fibres 1 to 3 and 4 to 6 were from the EDL
. Relative f-actin signal per nucleus is normalized to the average
conjugated Phalloidin penetrates equally throughout the
tack of a representativemyofibre, with the gray bar indicating a
is line section. Signal is not diminished in the core of the
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uncertain depth of the z-axis. Since confocal microscopy allows
accurate definition of the z-axis of the focal plane it is possible to
obtain more accurate measurement of signal quantity per sample
volume. However, with most designs of confocal microscope,
confocal z-stacks require long exposures that bleach the imaged
region of the myofibre. This bleaching prevents us from stitching
overlapping regions of confocal images to estimate the signal per
myofibre. We therefore compared ratios of fluorescent phalloidin
signal per nucleus, evaluated on whole myofibres by epifluores-
cence microscopy and subsequently as sample segments of the
same fibers by confocal microscopy. Comparison of two sets of
three myofibres from mice of two different ages showed excellent
agreement between the twomethods (Fig. 2C) (the relationship of
age to myofibre f-actin content is being explored more fully in a
separate investigation). Confocal z-stacks also showed that the
mounting procedure (a standard slide and coverslip) flattens the
myofibre, squashing its z-axis into a wide x–y profile. This may
contribute to the close agreement of the confocalized with the
non-confocalized data, suggesting that the 10X objective used for
the non-confocalized data gathers light emitted from the full z-axis
depth of the mounted myofibre.
A representative confocal image collected at the z-axis mid-
point of a myofibre produces equal signal intensity across the
myofibre (Fig. 2D), suggesting that fluorophore-conjugated phal-
loidin has full access to the core of the myofibre such that f-actin
quantity will not be underestimated for myofibres with large
cross-sections.
Ex vivo diminution of the myonuclear domain is not associated
with loss or replacement of myonuclei
Over two weeks of ex vivo maintenance we observe a decline in
size of isolated myofibres and decreasing spacing of nuclei
(Fig. 3A). Using f-actin signal per nucleus at various time-points
following isolation as an indicator of atrophy (Fig. 3B), we observe
a drop-off of ~35% per week, similar to that observed for in vivo
denervation, tenotomization, and hind-limb suspension studies of
muscles predominant in type II myofibres [6–8,10,13]. Over this
period, the number of nuclei per myofibre remains constant,
averaging around 330, with considerable variation between
individual myofibres (nuclear number per fibre ranged from less
than 100 to over 700). The drop in fibrous actin content was
paralleled by a 38% drop-off in total protein content between Day
0 and Day 9 (Fig. 3C).
The single myofibre model consists of both the myofibre and
adherent cells, largely quiescent satellite cells. To evaluate the role
of this adherent cell component of the system, we isolated
myofibres from the transgenic mouse strain MLC3F-LacZ, of
which myonuclei express LacZ driven by the promoter of Myosin
Light Chain type 3F [32] which permits discrimination between
myonuclei and nuclei of adherent cells (Fig. 4A). As in previous
studies [4,34], adherent cell numbers are negligible in relation to
myonuclear numbers in freshly isolated mouse EDL myofibres
(Fig. 4B). Unexpectedly however, most adherent cells are lost by
day 5 in floating suspension, in the low-growth medium in which
they were maintained. We speculate that adherent cells migrate
off the surface of the myofibre into the culture medium, either
remaining there or adhering to the plastic of the Petri dish. Parallel
experiments, using the same media and culture conditions, inwhich fibres were adhered to matrigel (instead of free-floating)
exhibited abundant proliferation of myoblasts beyond 5 days,
suggesting that myoblasts are unlikely to undergo cell death in the
suspension model. Since the contribution of adherent cell nuclei to
nuclear counts is negligible, there is no significant change in
myonuclear numbers throughout the time-course, thus the myo-
nuclear domain shrinks. There remains the possibility that
myonuclei apoptose and are replaced by newly proliferated
myoblasts to maintain myonuclear number. To test this possibility
we cultured myofibres in the constant presence of a nucleotide
analogue (EdU), then at days 2 and 5 fixed and stained them for
EdU and Pax7/MyoD (Fig. 4C). Co-staining with a mix of Pax7 and
MyoD antibodies allowed identification of both quiescent and
activated myoblasts. At day 2 a low level of labeling, just over 2
EdU positive nuclei per myofibre (Fig. 4D), was observed that by
Day 5 had dropped to just 1 such nucleus among 25myofibres, and
this was positive for Pax7/MyoD. Thus there is no fusion of
proliferated myoblasts to the myofibre to replace myonuclei and
thus apoptosis of myonuclei is either non-existent or very rare.
Characterization of gene expression
In an effort to better understand upstream changes preceding
atrophy, we measured gene expression levels, comparing freshly
isolated (Day 0) myofibres with ex vivo cultured myofibres at Days
1 and 2. Batches of 160 myofibres, in triplicate, were collected at
these time-points and mRNA was isolated. A microarray analysis
identified 2061 genes that were significantly altered between Day
0 and Day 2 (Supplemental Table 1). We selected 44 of these based
on their relevance to pathways of interest, and combined these
with a further 12 genes of interest that had not been identified by
microarray, to yield a final list of 56 genes whose mRNAs were
quantified by rtPCR (Table 1).
It must be borne in mind that the ex vivo myofibre model
includes not only the myofibre but also a small population of
adherent cells (almost exclusively myoblasts), representing
around 1–2% of the total nuclei, so these data require cautious
interpretation. Regarding genes of which we expect a significant
presence in the myofibre only, we detect downregulation of
several genes associated with the contractile apparatus, including
myosin heavy chain, titin, and dystrobrevin. The observed
upregulation of proteasomal subunits and ubiquitinylation en-
zymes is in keeping with a general degradation of protein content,
as measured by loss of f-actin and of total protein. Upregulation
of Proteasome subunit C9 is in agreement with a previous
denervation study [35]. Downstream effectors of the mTOR
pathway, a putative major regulatory axis of skeletal muscle
mass, are shifted to the atrophic state. The E3 ubiquitin protein
ligases atrogin-1 and MuRF-1 are both upregulated by days 1 and
2, suggestive of increased protein degradation. The eukaryotic
translation initiation factor 4E binding protein 1 (Eif4ebp1; also
known as PHAS-1), a negative regulator of the protein initiation
factor eIF-4E, is also upregulated, suggesting a suppression of
protein synthesis. Akt1 and Foxo1 are upregulated and down-
regulated respectively, but their activity is reported to be heavily
regulated at the protein phosphorylation level, which we did not
measure. The massive upregulation of tribbles homolog 3 may be
relevant here since it is reported to inhibit Akt1 phosphorylation.
The proteolytic gene, caspase 3 is upregulated. This is consistent
with the recent demonstration that Caspase 3 is required for
Fig. 3 – PhAct method applied to the ex vivo myofibre model. (A) Myofibre shrinkage during ex vivo culture. A representative
myofibre is shown at each of day 0, 7, and 14. Each of these examples have a similar total number of nuclei. Myofibre size and
distance between nuclei are observed to decrease with time. Scale bar=100 μm. (B) f-Actin content per nucleus diminishes with
time in ex vivo culturewhile nuclear number permyofibre is unchanged. Data are averages of from7 to 21myofibres per time-point.
For clarity, 95% confidence intervals are shown in one direction only. (C) Relative f-actin content measured by PhAct is similar to
relative total protein content. At days 0 and 9, the number of myofibres analyzed by PhAct was 35 and 27 respectively. Total protein
was measured by quantification of silver stain intensity of SDS-PAGE-separated whole protein extracts from batches of 20
myofibres. Total protein data are averages of 4 and 7 batches (totaling 80 and 140myofibres) at days 0 and 9 respectively. Confidence
intervals (95%) are shown and t-test statistical significances for day 0 against day 9 are indicated (* p<0.01; *** p<0.00001).
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the association of Caspase 3 activity with apoptosis, we show
(above) that apoptosis is not an observed feature of the isolated
myofibremodel. Another gene involved in proteolysis, Calpain 3, is
downregulated, likely reflecting its regulatory role, which has been
well documented post-denervation [37]. A number of other
changes in mRNA expression are listed, including alteration of
the NF-kB pathway, upregulation of two mitochondrial genes,
perhaps because of ex vivo exposure to atmospheric oxygen levels,
and massive downregulation of Aquaporin 4, which may be
expected if adjustment is required to a subtly different osmotic
environment.
The isolated myofibre as a model for testing potential modifiers
of atrophy
Having established the isolated myofibre as an ex vivo model of
atrophy, we attempted to alter the rate of atrophy by in vitro
administration of several putative modulators of muscle mass.
Various concentrations and regimes of administration were used,
in which substances were added to the culture medium of the
myofibres (Table 2). We observed a significant (p<0.05) increase
in rate of atrophy with Myostatin administration at 10 ng/ml, butthe effect was slight (by day 6 there was a 35% loss of f-actin as
opposed to a 28% loss by untreated controls) and no change was
observed at the other concentrations used (data not shown).
Administration of Follistatin, contrary to naïve expectation,
increased the rate of atrophy: by day 9 there was a 54% loss of f-
actin as opposed to a 40% loss by untreated controls (p<0.05; data
not shown). The rate of atrophy was unaffected by administration
of Leucine at the concentrations shown.Discussion
Ex vivomaintenance of the isolatedmyofibre as amodel for the
investigation of muscle atrophy
Since cross-sections of both healthy and atrophic skeletal muscle
tissue comprise almost entirely of myofibres, muscle atrophy
comes at the cost of myofibre mass. Despite the broad range of
pathologies that involve muscle atrophy (recent reviews: [5,38–
41]), diminution of myofibre cross-sectional area may be a
universal feature. To our knowledge, a decline of myofibre number
is rarely reported [42]. As well as in vivo, muscle atrophy has also
been investigated in vitro using cultured myotubes. The ex vivo
Fig. 4 –Myonuclei are not lost or replaced during ex vivo culture. (A) Micrographs showing DAPI-stained nuclei in blue andmyofibre
in brightfield (left panel) and myonuclei in red (right panel). The myofibre is isolated from a transgenic mouse exhibiting
myonuclear-specific expression of β-galactosidase (β-gal), permitting labeling with antibody against β-gal. The arrow indicates the
unlabeled nucleus of an adherent cell. Scale bar=100 μm. (B) Satellite and other adherent cells are lost during ex vivo culture.
Average numbers of β-gal negative nuclei per myofibre are shown for days 0 and 5, with 95% confidence intervals. T-test statistical
significance is indicated for day 5 against day 0 (**p<0.001). Thus maintenance or increase of adherent cell number does not
contribute to maintenance of nuclear number per myofibre. (C) Micrographs showing a section of a myofibre in brightfield
(upper-left panel), DAPI-stained nuclei in blue (upper-right panel), and a cluster of myoblast nuclei labeled with both EdU
(lower-left panel) and with an anti-Pax7/MyoD co-stain (lower-right panel). Scale bar=100 μm. (D) Myonuclei are not replaced by
proliferating myoblasts. Myofibres were cultured in the presence of the nucleotide analogue, EdU. EdU positive nuclei and nuclei
positive for one or both of themyoblastmarkers, Pax7 andMyoD, were counted at days 0, 2, and 5. Proliferated nuclei are extremely
rare by day 5 and are positive for myoblast markers. Confidence intervals (95%) are shown and t-test statistical significance is
indicated (** p<0.001; *** p<0.00001, NS=not significant) for days 2 and 5 against day 0 (Pax7/MyoD) or for day 5 against day 2
(EdU).
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diate model between the in vivo and in vitro approaches, having
many of the advantages of each. Prior to isolation, themyofibre has
developed to full maturity in the presence of innervation, tendonal
attachment, normal muscular architecture and vascularization,
and the in vivo cytokine environment. After isolation, the myofibre
loses neural stimulation and its tendinous attachments via which
to perform mechanical work. It thus represents a model of disuse/
denervation atrophy whose environment can be controlled on
many levels including nutritional availability, oxygen potential,
exposure to cytokines and to potential therapeutic compounds.
Sufficient numbers of myofibres can be obtained from a single EDLmuscle to allow performance of a fully internally controlled
experiment, thereby reducing the number of animals to what is
required to cover inter-animal variation.
The originators of the intact myofibre isolation method
investigated certain physiological and morphological properties
of collagen-adhered myofibres of the rat Flexor Digitorum Brevis
(FDB) during several days ex vivo, noting various changes
consistent with in vivo denervation, but some of which were
relatively delayed [2]. Wemaintainedmyofibres of themurine EDL
muscle in free-floating suspension in a ‘low growth’ culture
medium, thereby denying a substrate for the long-term prolifer-
ation and fusion of associated myoblasts. The ex vivo rate of
Table 1 – List of genes showing change in mRNA levels during ex vivo culture of isolated myofibres. Measurements made using
microarray and rtPCR methods are shown. Fold-change at day 1 or day 2 is given relative to day 0.
Day 0 v Day 1 Day 0 v Day 2
Category Gene Description Microarray rtPCR Microarray rtPCR
Proteasome Psma1 Proteasome subunit (C2) 1.39 1.49 1.67 1.81
Psma4 Proteasome subunit (C9) 1.15 1.60 1.71 1.66
Psmd5 Proteasome subunit (S5B) 3.27 3.22 4.86 6.70
Ubiquitinylation Ube1dc1 Ubiquitin-activating enzyme (E1) 4.63 6.54 4.54 7.73
Ube2l3 Ubiquitin-conjugating enzyme (E2) 1.46 2.08 1.51 2.16
mTOR related Akt1 Akt1 8.69 7.98
Frap1 mTOR 1.28 1.17
Foxo1 Forkhead box O1 − 3.97 − 2.87
Fbxo32 Ubiquitin protein ligase (E3)
(atrogin-1) 2.36 1.47
Trim63 Ubiquitin protein ligase (E3) (MURF-1) 3.53 1.53
Eif4ebp1 Eukaryotic translation initiation
factor 4E binding protein 1 2.46 4.10 3.73 5.22
Structural Actc1 Actin, alpha, cardiac − 2.10 1.09 − 4.16 − 1.07
Des Desmin 1.73 1.67
Dtna Dystrobrevin alpha − 2.74 − 2.20 − 5.02 − 4.20
Myh1 Myosin heavy chain 1 − 1.41 − 1.73 − 1.99 − 3.81
Myom2 Myomesin 2 − 1.95 1.20 − 2.40 − 1.38
Tnnt2 Troponin T2, cardiac 1.06 1.69 32.32 47.43
Tpm2 Tropomyosin 2, beta − 1.56 − 1.10 − 2.56 − 1.39
Ttn Titin − 3.32 − 1.85 − 4.93 − 3.34
Vim Vimentin 3.10 6.10 5.52 7.20
Proteolysis Capn3 Calpain 3 − 4.37 − 3.61 − 7.36 − 5.29
Casp3 Caspase 3 3.61 7.47
NF-kB related Ikbkg Inhibitor of kappaB kinase gamma 2.84 10.56 5.08 22.36
Mtpn Myotrophin 4.91 7.00 6.54 9.16
Nfkbia NFk light chain gene enhancer in B-
cells inhibitor, alpha 2.02 3.33 3.03
Nfkbie NFk light polypeptide gene
enhancer in B-cells inhibitor, epsilon 4.12 8.54 7.97 17.95
1.91
Nfkbiz NFk light polypeptide gene
enhancer in B-cells inhibitor, zeta − 7.19 − 2.36 − 3.67 − 1.01
Plcd4 Phospholipase C, delta 4 − 63.87 − 23.28 − 59.79 − 45.43
Tnfaip2 Tumor necrosis factor, alpha-
induced protein 2 − 9.98 − 4.36 − 5.85 − 2.36
Denervation Car3 Carbonic anhydrase 3 − 1.21 1.25 − 2.34 − 1.23
Ckm Creatine kinase 1.06 − 1.20
Lysosome Ctsa Cathepsin A − 1.79 1.24 − 2.85 1.31
Ctsc Cathepsin C − 7.83 − 2.72 − 8.43 − 4.17
Growth Factor Ctgf Connective tissue growth factor − 4.70 − 10.45 −12.71 − 5.33
Igtp Interferon gamma induced GTPase − 5.44
− 5.61 − 3.05 − 2.28
Iigp2 Interferon inducible GTPase 2 − 6.95 − 4.57 − 4.64 − 2.91
(continued on next page)
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Day 0 v Day 1 Day 0 v Day 2
Category Gene Description Microarray rtPCR Microarray rtPCR
Proteasome Psma1 Proteasome subunit (C2) 1.39 1.49 1.67 1.81
Psma4 Proteasome subunit (C9) 1.15 1.60 1.71 1.66
Psmd5 Proteasome subunit (S5B) 3.27 3.22 4.86 6.70
Ubiquitinylation Ube1dc1 Ubiquitin-activating enzyme (E1) 4.63 6.54 4.54 7.73
Ube2l3 Ubiquitin-conjugating enzyme (E2) 1.46 2.08 1.51 2.16
mTOR related Akt1 Akt1 8.69 7.98
Frap1 mTOR 1.28 1.17
Foxo1 Forkhead box O1 − 3.97 − 2.87
Fbxo32 Ubiquitin protein ligase (E3)
(atrogin-1) 2.36 1.47
Trim63 Ubiquitin protein ligase (E3) (MURF-1) 3.53 1.53
Eif4ebp1 Eukaryotic translation initiation
factor 4E binding protein 1 2.46 4.10 3.73 5.22
Structural Actc1 Actin, alpha, cardiac − 2.10 1.09 − 4.16 − 1.07
Des Desmin 1.73 1.67
Dtna Dystrobrevin alpha − 2.74 − 2.20 − 5.02 − 4.20
Myh1 Myosin heavy chain 1 − 1.41 − 1.73 − 1.99 − 3.81
Myom2 Myomesin 2 − 1.95 1.20 − 2.40 − 1.38
Tnnt2 Troponin T2, cardiac 1.06 1.69 32.32 47.43
Tpm2 Tropomyosin 2, beta − 1.56 − 1.10 − 2.56 − 1.39
Ttn Titin − 3.32 − 1.85 − 4.93 − 3.34
Vim Vimentin 3.10 6.10 5.52 7.20
Proteolysis Capn3 Calpain 3 − 4.37 − 3.61 − 7.36 − 5.29
Casp3 Caspase 3 3.61 7.47
m
r in
eps
zet
or
Pa
Anabolis Eif2s1 Eukaryotic translation initiation factor
2, subunit 1 alpha 2.16 3.08 2.48 2.78
Remodelling Hspa1a Heat shock protein 1A − 29.37 − 12.83 − 30.57 − 8.52
Hspa1b Heat shock protein 1B − 19.48 − 12.83 − 23.28 − 8.52
Mitochondrial Cat Catalase 2.33 4.86 4.73 8.70
Gsr Glutathione reductase 1 2.03 22.04 4.04 50.71
Sod1 Superoxide dismutase 1, soluble 1.10 1.23 1.35 1.36
Fibrosis Col22a1 Collagen, type XXII, alpha 1 − 5.31 − 1.46 − 13.71 − 5.03
Col9a1 Procollagen, type IX, alpha 1 − 4.32 − 1.75 − 7.65 − 7.20
Myogenesis Msc Musculin − 6.58 − 8.97 − 10.45 − 10.05
Myf5 Myogenic factor 5 2.77 2.84
Myod1 Myogenic differentiation 1 − 2.16 1.17
Myog Myogenin 3.21 33.41
Peg3 Paternally expressed 3 (PW1) 3.05 9.89 2.93 5.71
Miscellaneous Aqp4 Aquaporin 4 − 10.21 − 7.74 − 51.13 − 64.49
Gsn Gelsolin − 8.08 − 2.83
Musk Muscle, skeletal, receptor tyrosine
kinase 2.32 1.89 8.65 12.58
Myoz1 Myozenin 1 − 2.70 1.22 − 5.93 − 1.31
S100a6 S100 calcium binding protein A6
(calcyclin)  2.73 5.66 14.04 18.33
Socs3 Suppressor of cytokine signaling 3 − 43.35 − 24.01 − 25.64 − 25.10
Trib3 Tribbles homolog 3 (Drosophila) 11.23 152.47 36.92 473.92
Table 1 (continued)
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Growth Factor Ctgf Connective tissue growth fact
Igtp Interferon gamma induced GT
Iigp2 Interferon inducible GTPase 2
atrophy we observe is the same as that measured for in vivo
denervation [6,13], tenotomization [8], and hindlimb suspension
[7,10] of muscles predominant in type II myofibres. Type I
myofibres can also be isolated from the soleus [3], and for those
we would expect a faster rate of atrophy, as observed with in vivo
tenotomization of the soleus [8].
The PhAct method
Fig. 5 gives a schematic overview of PhAct. Fluorescence signal
from actin-bound fluorophore conj gates of the m ll molecule
toxin, Phalloidin, is used as an index of f-actin content per
myofibre. Phalloidin binds specifically to actin filaments, not to
monomeric actin. In combination with c unts of nuclei the f-actin
content per nucleus is obtained. Plots of f-actin content against
nuclear number combines the two main components of muscle
fibre size into a pattern, shifts of which provide quantitative
descriptors of the cellular mechanisms behind atropic and
hypertropic changes wrought by a variety of treatments. Vertical
displacements portray atrophy or hypertrophy generated by
reduction or increase respectively in myonuclear domain. Con-
versely, horizontal displacements i dicate changes in fibre size
associated with loss or gain of myonuclear number. A major
feature of this form of ex vivo analysis is that it can be applied toa 2.84 10.56 5.08 22.36
4.91 7.00 6.54 9.16
 B- 2.02 3.33 3.03
ilon 4.12 8.54 7.97 17.95
1.91
a − 7.19 − 2.36 − 3.67 − 1.01
− 63.87 − 23.28 − 59.79 − 45.43
− 9.98 − 4.36 − 5.85 − 2.36
− 1.21 1.25 − 2.34 − 1.23
1.06 − 1.20
− 1.79 1.24 − 2.85 1.31
− 7.83 − 2.72 − 8.43 − 4.17
− 4.70 − 10.45 −12.71 − 5.33
se − 5.44
− 5.61 − 3.05 − 2.28
− 6.95 − 4.57 − 4.64 − 2.91
fibres that have been isolated after induction of atrophy or
hypertrophy in vivo, and can thus be used to compare the actions
of individual strategies or agents in vivo and in vitro.
Decline in f-actin content closely parallels that of total protein
over nine days of myofibre ex vivo maintenance, suggesting that f-
actin content is an accurate indicator of overall change in myofibre
mass. Previous studies have usedWestern Blotting tomeasure Actin
and Myosin Heavy Chain contents in various atrophic conditions in
vivo[9,15,43–47]. Actin loss at a rate similar to orgreater thanMyosin
Heavy Chain has been reported following denervation of mouse
Gastrocnemius muscle [47] and decline of both Actin and Myosin
Heavy Chain synthesis during mouse hindlimb suspension has been
detected at the mRNA level after one day and the protein level after
two days [9]. Actin is also lost at a similar rate toMyosinHeavy Chain
in humans during bed-rest [43] and following prolonged diaphragm
disuse [44]. However, one study described a two-fold faster decline
of Myosin Heavy Chain than Actin following rat spinal cord isolation
[48], and early loss of Actin without loss of MHC is observed in vitro
following 32 hour treatment of cultured myotubes with dexameth-
asone [15]. Myosin Heavy Chain has been described to decline
without any loss of Actin during cachexia [45], Application of the
PhAct method should determine whether differences exist in the
quantitative characteristics of actin loss between forms of atrophy
such as cachexia. Other indicators of the importance of actin content
Table 2 – Effects of several putative modifiers of muscle
mass on rate of atrophy.
Molecule Concentration(s) Regime Effect on rate of
atrophy
Myostatin 10 ng/ml, 100 ng/ml,
500 ng/ml
Every 3 days for
6 days
↑ (at 10 ng/ml)
Follistatin 100 ng/ml Every 3 days for
9 days
↑
Leucine 0.2 mM, 5 mM,
10 mM
Every 3 days for
6 days
None detected
1989E X P E R I M E N T A L C E L L R E S E A R C H 3 1 7 ( 2 0 1 1 ) 1 9 7 9 – 1 9 9 3in the context of muscle mass are that actin synthesis is decreased
with age in rats [46] and that actin mRNA levels and protein
synthesis rate recover quickly on muscle reloading following
hindlimb suspension in rats [49].Fig. 5 – Schematic overview of the PhAct method wiThe PhAct method is suitable for general application to small
animalmodels of muscle growth and disease, where it is of interest
to assay the effects of in vivo treatments and interventions. The
method is sensitive and convenient, since the isolation of
myofibres is now a routine tool of the field. It has the advantage
over existing approaches of providing information at the cellular
(per myofibre) level. Existing approaches to the assay of change in
muscle mass in vivo are limited to coarse measurement of whole
muscle weight and protein content [6–9] or to indirect inferences
from muscle cross-sections [10–12]. The major alternative,
myotube tissue cultures, are valuable for analysis of molecular
mechanisms but of questionable relevance to control of muscle
size in vivo[14–16]. One recent study describes estimation of
isolated myofibre volume using standard microscopy equipment
[33] by a combination of cross-sectional data with measurements
of myofibre length but does not provide information on proteinth explanation of how data may be interpreted.
1990 E X P E R I M E N T A L C E L L R E S E A R C H 3 1 7 ( 2 0 1 1 ) 1 9 7 9 – 1 9 9 3content. Measurement of cross-sectional area per myofibre is the
most common approach to the assay of change in muscle mass at a
cellular level, but it is prone to inaccuracies due to the orientation
of the muscle during sectioning, and takes no account of myofibre
length.
Ex vivo myofibre atrophy occurs without loss or replacement
of myonuclei
Since we observe a decreased size and protein content of
myofibres following ex vivo maintenance but with no loss or
replacement of myonuclei we conclude that the myonuclear
domain is diminished and that myonuclear apoptosis is either
absent or rare. We find that myofibres of the predominantly ‘fast’
EDL muscle show very similar rates of actin and total protein loss
during ex vivomaintenance to in vivomodels of denervation [6,13],
tenotomization [8], and hindlimb suspension [7,10]. In one such
study, time-lapse microscopy was used to demonstrate loss of
cross-sectional area without loss of myonuclei over several weeks
of in vivo denervation of the EDL and Soleus muscles [13]. These
findings are consistent with reports of fast-twitch myofibre
atrophy without detectable myonuclear loss in various contexts,
such as denervation of rat diaphragm [17], denervation of plantaris
muscles of mature mice (although somemyonuclear loss was seen
in myofibres of young mice) [18], of rat plantaris after spinal cord
transection [27], of rat Soleus after spinal cord isolation [19], of rat
Soleus and Plantaris muscles after 28-day hindlimb suspension
[20], and short-term spaceflight induced atrophy of the Soleus
muscle of the Rat [21,24] and the Rhesus monkey [22] and of Rat
Tibialis Anterior and Gastrocnemius [23]. These findings support
the paradigm that inactivation-induced atrophy occurs primarily
via diminution of the myonuclear domain, and does not require
myonuclear apoptosis, at least in the case of fast-twitch myofibres.
Several studies report loss of myonuclei and/or increased
apoptosis in situations of atrophy or reduced functional demand
[24–27,50–52] (reviewed here [53]). Exclusively this is reported for
slow-twitch myofibres in environments featuring a transition from
type I to type II MHC expression such as occurs in the Soleus muscle
duringhindlimb suspension [26,54] and spaceflight [24]. Fast-twitch
myofibres have fewer nuclei than slow-twitch, and spinal isolation
has been associated with the appearance of fast-twitch myofibres
that may have switched fibre type and undergone significant
myonuclear loss [25]. One study reports no loss ofmyonuclei despite
massive Soleus myofibre atrophy following Rat spinal cord isolation
[19]. Regardless of the extent to which myonuclei are lost and
whether fibre-type switching is involved, atrophy of slow-twitch
myofibres likely involves a diminution of the myonuclear domain,
since the reported loss of cytoplasmic volume is usually dispropor-
tionate to the loss of myonuclei [19,24–26].
A number of studies [25,55–60] report increased myonuclear
numbers in various myofibre types when functional demand is
increased, and in this context there is a commensurate change in
cytoplasmic volume such that myonuclear domain size is main-
tained. This commensurate change may not be simultaneous, but
reports are conflicting over which occurs first. A recent report shows
myonuclear accretion to precede the occurrence of hypertrophy in
response to increased functional demand in the mouse EDL [60] but
this appears contradictory to findings in overloaded rat Plantaris [61].
Thus diminution of the myonuclear domain may be the primary
response to inactivity and disuse, since myonuclear loss need notprecede muscle atrophy, but size of the myonuclear domain is
maintained following muscle hypertrophy.
Characterization of early changes in gene expression in the
ex vivo myofibre atrophy model
Atrophy-associated changes towholemuscle gene expression have
been characterized in small mammals [62–66] and humans [67–
70], and are generally consistent with the putative designation of
the E3 ubiquitin protein ligases as the primary down-stream
effectors ofmyofibre shrinkage [63]. Models of associated signaling
pathways have been proposed (reviewed [38,40,41]). The present
study is the first to profile mRNA expression of only the myofibre
with its associated satellite cells, eliminating vasculature and other
interstitial tissue that may confound gene expression analyses. We
measured changes occurring over the first 48 hours of single
myofibre ex vivomaintenance. Microarray profiling identified 2061
significantly altered genes and an overlapping set of 56 mRNAs
were quantified by rtPCR. The observed changes were consistent
with increased proteolytic and proteasomal activity, including
upregulation of the E3 ubiquitin protein ligases atrogin-1 and
MuRF-1, upregulation of Eif4ebp1, a negative regulator of the
protein initiation factor eIF-4E, and downregulation of major
contractile components such as Myosin Heavy Chain and Titin.
These data serve as a baseline for comparison against future
manipulations of the ex vivomyofibre maintenance model, such as
to test whether anti-atrophic compounds affect mRNA levels.
Influences of cytokines on the rate of ex vivo atrophy
Since the identification of Myostatin as an important negative
regulator of muscle mass [28] much effort has gone into the
identification of means to block its activity, such as via the
inhibitory glycoprotein, Follistatin (for review see [71]). We detect
a small increase in rate of atrophywith the addition of Myostatin at
10 ng/ml but not at 100 or 500 ng/ml. This is suggestive of a
bimodal response, which has not been noted previously [72,73].
Recently it has been shown that in vivo muscle hypertrophy
induced by myostatin blockade occurs without a rise in myo-
nuclear number, indicating that myoblast fusion is not required
[74], despite observations of myoblast behavioural regulation by
high concentrations of myostatin [75–78]. Questions such as this
can now be more sensitively resolved by measuring subtle in vivo
change to muscle mass using the PhAct method. Our method of
quantitative analyses of myonuclear number and fibrous actin
content can be applied directly to muscle fibres isolated after in
vivo atrophic and hypertrophic treatments. It should prove a useful
tool in disentangling effects directly on the muscle fibre, from
those that are mediated by various in vivo interactions. Interest-
ingly, and contrary to expectation, Follistatin administration also
increased the rate of atrophy in our isolated fibre preparations, a
marked contrast to its reported action in vivo[29,79], that merits
further investigation.
This work establishes the ex vivo myofibre as a suitable model
for the testing of potential modifiers of atrophy, such as screening
of compounds for their anti-atrophic properties. Its principal
limitations arise from both practical and theoretical causes.
Practically, it is effectively limited to muscles from which we can
dissociate single fibres. Some problems of interpretation may arise
where the muscle consists of very disparate populations of muscle
1991E X P E R I M E N T A L C E L L R E S E A R C H 3 1 7 ( 2 0 1 1 ) 1 9 7 9 – 1 9 9 3fibres, e.g. the tibialis anterior where the superficial and deep
regions differ significantly from one another. The usefulness of the
technique would also be improved if we were able to reliably
distinguish fibre types; up to now, our attempts to do so by
immunostaining for myosin heavy chain isoforms have been foiled
by high background signal, but we would expect that this will be
resolved by technical refinement. As it stands, this protocol would
not easily transfer between laboratories because of the arbitrary
normalization of fluorescent signal to a standard concentration of
fluorescent phalloidin. However, calibration to a primary refer-
ence, such as a known concentration of fibrous actin protein in
agar would facilitate comparisons between individual studies.
Balanced against these problems is the fact that the isolated fibre
protocol presents us with an experimentally accessible model of
muscle atrophy as it applies tomaturemuscle fibers, that can be used
to pick apart themechanisms behind the control ofmuscle size and of
treatments and agents that mediate this control. To advance work in
this topic from its current largely empirical status we need to gather
information on mechanisms at the cellular as well as the molecular
levels of organization. It will be of interest, for example, to examine
combined administrations of Myostatin and Follistatin both in vivo
and in our ex vivo system and to compare the cellular responses as
well as the early gene expression changes they induce in each case.
Supplementary materials related to this article can be found
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